{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:57:47Z","timestamp":1792612667417,"version":"4.5.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2007,8,7]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>Background\u2014<\/jats:italic>\n            <\/jats:bold>\n            In individuals without known cardiovascular disease, elevated body mass index (BMI) (weight\/height\n            <jats:sup>2<\/jats:sup>\n            ) is associated with an increased risk of death. However, in patients with certain specific chronic diseases, including heart failure, low BMI has been associated with increased mortality.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Methods and Results\u2014<\/jats:italic>\n            <\/jats:bold>\n            We examined the influence of BMI on prognosis using Cox proportional hazards models in 7599 patients (mean age, 65 years; 35% women) with symptomatic heart failure (New York Heart Association class II to IV) and a broad spectrum of left ventricular ejection fractions (mean, 39%) in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. During a median follow-up of 37.7 months, 1831 patients died. After adjustment for potential confounders, compared with patients with BMI between 30 and 34.9, patients in lower BMI categories had a graded increase in the risk of death. The hazard ratios (95% confidence intervals) were 1.22 (1.06 to 1.41), 1.46 (1.24 to 1.71), and 1.69 (1.43 to 2.01) among those with BMI of 25 to 29.9, 22.5 to 24.9, and &lt;22.5, respectively. The increase in risk of death among patients with BMI \u226535 was not statistically significant (hazard ratio, 1.17; 95% confidence interval, 0.95 to 1.43). The association between BMI and mortality was not altered by age, smoking status, or left ventricular ejection fraction (\n            <jats:italic>P<\/jats:italic>\n            for interaction &gt;0.20). However, lower BMI was associated with a greater risk of all-cause death in patients without edema but not in patients with edema (\n            <jats:italic>P<\/jats:italic>\n            for interaction &lt;0.0001). Lower BMI was associated with a greater risk of cardiovascular death and noncardiovascular death. Baseline BMI did not influence the risk of hospitalization for worsening heart failure or due to all causes.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Conclusions\u2014<\/jats:italic>\n            <\/jats:bold>\n            In patients with symptomatic heart failure and either reduced or preserved left ventricular systolic function, underweight or low BMI was associated with increased mortality, primarily in patients without evidence of fluid overload (edema).\n          <\/jats:p>","DOI":"10.1161\/circulationaha.106.679779","type":"journal-article","created":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T00:44:24Z","timestamp":1184633064000},"page":"627-636","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":352,"title":["Body Mass Index and Prognosis in Patients With Chronic Heart Failure"],"prefix":"10.1161","volume":"116","author":[{"given":"Satish","family":"Kenchaiah","sequence":"first","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (S.K., P.V.F., L.A.M.Z., H.S., M.A.P., S.D.S.); Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK (S.J.P., D.W.); McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (S.Y.); Sahlgrenska Academy, Go\u0308teborg University, Go\u0308teborg, Sweden (K.S.); AstraZeneca LP, Wilmington, Del (E.L.M.); Duke University Medical..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (S.K., P.V.F., L.A.M.Z., H.S., M.A.P., S.D.S.); Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK (S.J.P., D.W.); McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (S.Y.); Sahlgrenska Academy, Go\u0308teborg University, Go\u0308teborg, Sweden (K.S.); AstraZeneca LP, Wilmington, Del (E.L.M.); Duke University Medical..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duolao","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (S.K., P.V.F., L.A.M.Z., H.S., M.A.P., S.D.S.); Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK (S.J.P., D.W.); McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (S.Y.); Sahlgrenska Academy, Go\u0308teborg University, Go\u0308teborg, Sweden (K.S.); AstraZeneca LP, Wilmington, Del (E.L.M.); Duke University Medical..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter V.","family":"Finn","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (S.K., P.V.F., L.A.M.Z., H.S., M.A.P., S.D.S.); Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK (S.J.P., D.W.); McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (S.Y.); Sahlgrenska Academy, Go\u0308teborg University, Go\u0308teborg, Sweden (K.S.); AstraZeneca LP, Wilmington, Del (E.L.M.); Duke University Medical..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo A.M.","family":"Zornoff","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (S.K., P.V.F., L.A.M.Z., H.S., M.A.P., S.D.S.); Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK (S.J.P., D.W.); McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (S.Y.); Sahlgrenska Academy, Go\u0308teborg University, Go\u0308teborg, Sweden (K.S.); AstraZeneca LP, Wilmington, Del (E.L.M.); Duke University Medical..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hicham","family":"Skali","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (S.K., P.V.F., L.A.M.Z., H.S., M.A.P., S.D.S.); Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK (S.J.P., D.W.); McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (S.Y.); Sahlgrenska Academy, Go\u0308teborg University, Go\u0308teborg, Sweden (K.S.); AstraZeneca LP, Wilmington, Del (E.L.M.); Duke University Medical..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (S.K., P.V.F., L.A.M.Z., H.S., M.A.P., S.D.S.); Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK (S.J.P., D.W.); McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (S.Y.); Sahlgrenska Academy, Go\u0308teborg University, Go\u0308teborg, Sweden (K.S.); AstraZeneca LP, Wilmington, Del (E.L.M.); Duke University Medical..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (S.K., P.V.F., L.A.M.Z., H.S., M.A.P., S.D.S.); Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK (S.J.P., D.W.); McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (S.Y.); Sahlgrenska Academy, Go\u0308teborg University, Go\u0308teborg, Sweden (K.S.); AstraZeneca LP, Wilmington, Del (E.L.M.); Duke University Medical..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (S.K., P.V.F., L.A.M.Z., H.S., M.A.P., S.D.S.); Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK (S.J.P., D.W.); McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (S.Y.); Sahlgrenska Academy, Go\u0308teborg University, Go\u0308teborg, Sweden (K.S.); AstraZeneca LP, Wilmington, Del (E.L.M.); Duke University Medical..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Michelson","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (S.K., P.V.F., L.A.M.Z., H.S., M.A.P., S.D.S.); Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK (S.J.P., D.W.); McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (S.Y.); Sahlgrenska Academy, Go\u0308teborg University, Go\u0308teborg, Sweden (K.S.); AstraZeneca LP, Wilmington, Del (E.L.M.); Duke University Medical..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (S.K., P.V.F., L.A.M.Z., H.S., M.A.P., S.D.S.); Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK (S.J.P., D.W.); McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (S.Y.); Sahlgrenska Academy, Go\u0308teborg University, Go\u0308teborg, Sweden (K.S.); AstraZeneca LP, Wilmington, Del (E.L.M.); Duke University Medical..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (S.K., P.V.F., L.A.M.Z., H.S., M.A.P., S.D.S.); Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK (S.J.P., D.W.); McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (S.Y.); Sahlgrenska Academy, Go\u0308teborg University, Go\u0308teborg, Sweden (K.S.); AstraZeneca LP, Wilmington, Del (E.L.M.); Duke University Medical..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (S.K., P.V.F., L.A.M.Z., H.S., M.A.P., S.D.S.); Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK (S.J.P., D.W.); McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (S.Y.); Sahlgrenska Academy, Go\u0308teborg University, Go\u0308teborg, Sweden (K.S.); AstraZeneca LP, Wilmington, Del (E.L.M.); Duke University Medical..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00126-6"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.7.996"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2001.00801.x"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020245"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199509143331101"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910073411501"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199106273242602"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07015-8"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2000.2533"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1054\/jcaf.2002.126812"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1054\/jcaf.2003.4"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi022"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.1.55"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(00)90023-1"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.88.1.8319323"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9164(99)90013-1"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14282-1"},{"key":"e_1_3_2_18_2","unstructured":"Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity Geneva June 3\u20135 1997. Geneva Switzerland: World Health Organization; 1998."},{"key":"e_1_3_2_19_2","unstructured":"Clinical Guidelines on the Identification Evaluation and Treatment of Overweight and Obesity in Adults. Bethesda Md: National Institutes of Health; 1998. Publication NIH 98-4083."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi555"},{"key":"e_1_3_2_21_2","unstructured":"SAS Institute Inc. SAS\/STAT User\u2019s Guide Version 9.1. Cary NC: SAS Institute Inc; 2004."},{"key":"e_1_3_2_22_2","first-page":"1563","volume":"39","year":"2002","unstructured":"Lavie CJ, Milani R, Mehra MR, Ventura HO, Messerli FH. Obesity, weight reduction and survival in heart failure. J Am Coll Cardiol. 2002; 39: 1563\u20131564.","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.11.039"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2004.04.011"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi055"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1999.1882"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001573-199905000-00004"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12892-9"},{"key":"e_1_3_2_29_2","first-page":"II-437.","volume":"104","year":"2001","unstructured":"Coats A, Anker SD, Roecker EB, Schultz MK, Staiger C, Amann-Zalan I, Shusterman N, Packer M. Prevention and reversal of cardiac cachexia in patients with severe heart failure by carvedilol: results of the COPERNICUS study. Circulation. 2001; 104 II-437.","journal-title":"Circulation"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01448-6"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.96.10.3423"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)01103-7"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00262-3"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.1.207-a"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.1999.277.3.H971"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.10.066"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000112582.16683.ea"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.97.21.2099"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03470020057032"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)80339-7"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00505-5"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00031-6"}],"updated-by":[{"DOI":"10.1161\/circulationaha.107.186042","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2007,8,7]],"date-time":"2007-08-07T00:00:00Z","timestamp":1186444800000}}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.106.679779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:27:28Z","timestamp":1715574448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.106.679779"}},"subtitle":["Insights From the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program"],"short-title":[],"issued":{"date-parts":[[2007,8,7]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,8,7]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.106.679779"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.106.679779","relation":{"correction":[{"id-type":"doi","id":"10.1161\/CIRCULATIONAHA.107.186042","asserted-by":"object"}]},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,7]]},"assertion":[{"value":"2007-07-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}